November 2019 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for November 2019. This roundup includes the latest...
Obesity Mediates Response to Antiarrhythmic Drugs in A-Fib
Reduced response to sodium versus potassium channel blocker AADs seen in obese patients, mice
Continuous PPI Use May Increase Risk for Acute Gastroenteritis
Risk for acute gastroenteritis icreased for all ages combined and for those aged 45 to 64, 65 to 74, ≥75
Diet Pill, Laxative Use in Women Tied to Later Eating Disorder Dx
Odds of incident eating disorder diagnosis up with use of diet pill, laxative for weight control
U.S. Adults With ASCVD Report Skipping Meds Due to Costs
Age <65 years, female sex, high comorbidity burden independently linked to cost-related nonadherence
Exposure to Psychoactive Substances Up From 2000 to 2017
Exposure to most substances decreased, but significant increases seen in marijuana, nutmeg, and kratom
Three Meds Equal as Second-Line Therapy for Status Epilepticus
Levetiracetam, fosphenytoin, valproate treat seizures unresponsive to benzodiazepine in children, adults
Taking Multiple Fracture-Linked Meds Ups Risk for Hip Fracture
Addition of second and third fracture-associated drugs linked to increased risk for women and men
Alarm Settings of CGM Systems Impact Glucose Control in T1DM
Adjusting glucose thresholds for alarms linked to less time spent in hypoglycemia, hyperglycemia
Dermatologists Issue Consensus Guideline for Opioid Prescribing
For most uncomplicated procedures, postop pain can be managed with acetaminophen and/or ibuprofen
